<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03282890</url>
  </required_header>
  <id_info>
    <org_study_id>H17-200</org_study_id>
    <secondary_id>R01DA044867</secondary_id>
    <nct_id>NCT03282890</nct_id>
  </id_info>
  <brief_title>Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs</brief_title>
  <acronym>CHRP-BB</acronym>
  <official_title>Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>APT Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and cost-effectiveness of CHRP-BB - an integrated&#xD;
      bio-behavioral approach that incorporates the use of PrEP - with an evidence-based behavioral&#xD;
      approach aimed at enhancing PrEP adherence and HIV risk reduction among high risk PWUD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PWUD remain a priority population as they represent a critical conduit for new HIV&#xD;
      infections, which are transmitted through preventable drug- and sex-related HIV risk&#xD;
      behaviors. Pre-Exposure Prophylaxis (PrEP) - the daily self-administration of antiretroviral&#xD;
      medication - has enormous potential to bolster primary HIV prevention outcomes among PWUD.&#xD;
      PrEP is a FDA-approved biomedical HIV prevention strategy recommended by the CDC and WHO for&#xD;
      key populations, including PWUD. Despite unequivocal evidence supporting PrEP, its scale-up&#xD;
      has been nearly absent among high risk PWUD. Moreover, adherence to PrEP is crucial if it is&#xD;
      to be effective with high risk individuals. Recent research, however, indicates that optimal&#xD;
      PrEP adherence may be compromised by neurocognitive impairment (NCI), particularly among&#xD;
      PWUD. Due to chronic drug use, related lifestyle experiences, and other health challenges,&#xD;
      many PWUD experience NCI to the extent that it impedes medication adherence, HIV risk&#xD;
      reduction, and treatment retention. In a recent HIV prevention trial, over a third of high&#xD;
      risk PWUD on opioid replacement therapy (ORT) had moderate to high levels of NCI and,&#xD;
      moreover, were less likely to reduce their HIV transmission risk vs. those without NCI. The&#xD;
      potentially disruptive impact of NCI must therefore be addressed when designing contemporary&#xD;
      intervention strategies targeting PWUD. Contemporary approaches must also be cost-effective&#xD;
      and usable in real-world treatment settings, such as methadone maintenance programs (MMPs)&#xD;
      where high risk PWUD are concentrated and can be readily reached with primary prevention. To&#xD;
      date, however, primary prevention efforts have largely relied on singular strategies (e.g.,&#xD;
      methadone or PrEP alone) with modest HIV risk reduction outcomes for PWUD. Instead, advancing&#xD;
      combination approaches capable of harnessing the synergy and efficiency possible via multiple&#xD;
      evidence-based strategies is most effective. This combination strategy is especially&#xD;
      important when intervening with high risk PWUD with NCI due to the potential decreased&#xD;
      effectiveness of PrEP when adherence is suboptimal, thereby necessitating behavioral&#xD;
      interventions that focus on reducing HIV risk and increasing PrEP adherence. Building on&#xD;
      promising preliminary work, the proposed trial will fill a critical void by testing an&#xD;
      integrated bio-behavioral approach that incorporates the use of PrEP with an evidence-based&#xD;
      behavioral approach and, using innovative strategies, enhances PrEP adherence and HIV risk&#xD;
      behavior in a manner that accommodates NCI among PWUD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PrEP adherence</measure>
    <time_frame>Over a 9-month period</time_frame>
    <description>PrEP Adherence will be assessed with Dried Blood Spots (DBS) and by self-report using the visual analogue scale (VAS) and pharmacy refill data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV risk reduction behaviors</measure>
    <time_frame>Over a 9-month period</time_frame>
    <description>A self-reported assessment will measure several aspects of HIV risk-taking behaviors, including a measurement of any high risk behavior (sexual or injection-related) as well as measurements of event-level (i.e., partner-by-partner) behaviors. &quot;Any&quot; risk behavior will be dichotomously parsed as those who have engaged in HIV transmission risk behaviors with those of unknown or HIV negative status. Urine toxicology tests will also be used to collect substance use data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IMB measures related to PrEP adherence and HIV risk reduction</measure>
    <time_frame>Over a 9-month period</time_frame>
    <description>Data collected at all assessment points will include our measure of IMB model constructs, including (a) Information - HIV risk- and PrEP-related knowledge; (b) Motivation - readiness to change and intentions to change PrEP adherence and change HIV risk behavior; (c) Behavioral Skills - PrEP adherence skills and HIV risk reduction skills; and (d) Behavioral Outcomes - HIV risk and HIV risk reduction behaviors and PrEP adherence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Risk Behavior</condition>
  <condition>HIV/AIDS</condition>
  <condition>Medication Adherence</condition>
  <condition>Substance Abuse</condition>
  <arm_group>
    <arm_group_label>CHRP-BB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Condition</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHRP-BB</intervention_name>
    <description>The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).</description>
    <arm_group_label>CHRP-BB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet DSM-V criteria for opioid-dependence and are enrolled in methadone maintenance&#xD;
             drug treatment at the APT Foundation, Inc.&#xD;
&#xD;
          -  Were confirmed to be HIV-negative and started on PrEP in the past week&#xD;
&#xD;
          -  Report unsafe injection drug use practices or unprotected sex within the past 3 months&#xD;
&#xD;
          -  Have a cell phone&#xD;
&#xD;
          -  Are able to read and understand the questionnaires, ACASI, and informed consent form&#xD;
&#xD;
          -  Available for the full duration of the study with no anticipated circumstances&#xD;
             impeding participation (e.g., pending charges, jail term).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have an untreated bipolar or psychotic disorder&#xD;
&#xD;
          -  Are actively suicidal or homicidal as assessed by trained research staff under the&#xD;
             supervision of a licensed clinical psychologist&#xD;
&#xD;
          -  Cannot speak English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Copenhaver, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Sibilio, BS</last_name>
    <phone>(203) 781-4690</phone>
    <email>brian.sibilio@uconn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roman Shrestha, PhD</last_name>
    <phone>(203) 781-4690</phone>
    <email>roman.shrestha@uconn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>APT Foundation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Sibilio, BS</last_name>
      <phone>203-781-4690</phone>
      <email>brian.sibilio@uconn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roman Shrestha, PhD</last_name>
      <phone>(203) 781-4690</phone>
      <email>roman.shrestha@uconn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael C Copenhaver, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chip.uconn.edu/</url>
    <description>University of Connecticut Institute for Collaboration on Health, Intervention, and Policy (InCHIP)</description>
  </link>
  <reference>
    <citation>Shrestha R, Altice F, Karki P, Copenhaver M. Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Front Immunol. 2017 May 11;8:561. doi: 10.3389/fimmu.2017.00561. eCollection 2017.</citation>
    <PMID>28553295</PMID>
  </reference>
  <reference>
    <citation>Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L, Copenhaver M. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017 Apr 1;173:107-116. doi: 10.1016/j.drugalcdep.2016.12.023. Epub 2017 Feb 2.</citation>
    <PMID>28214391</PMID>
  </reference>
  <reference>
    <citation>Huedo-Medina TB, Shrestha R, Copenhaver M. Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment. AIDS Behav. 2016 Aug;20(8):1646-57. doi: 10.1007/s10461-016-1394-x.</citation>
    <PMID>27052845</PMID>
  </reference>
  <reference>
    <citation>Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psychol Bull. 1992 May;111(3):455-74. doi: 10.1037/0033-2909.111.3.455.</citation>
    <PMID>1594721</PMID>
  </reference>
  <reference>
    <citation>Shrestha R, Huedo-Medina TB, Altice FL, Krishnan A, Copenhaver M. Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. AIDS Behav. 2017 Nov;21(11):3100-3110. doi: 10.1007/s10461-016-1637-x.</citation>
    <PMID>28025735</PMID>
  </reference>
  <reference>
    <citation>Copenhaver MM, Lee IC, Margolin A. Successfully integrating an HIV risk reduction intervention into a community-based substance abuse treatment program. Am J Drug Alcohol Abuse. 2007;33(1):109-20. doi: 10.1080/00952990601087463.</citation>
    <PMID>17366251</PMID>
  </reference>
  <reference>
    <citation>Copenhaver MM, Lee IC, Baldwin P. A randomized controlled trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment. AIDS Behav. 2013 Nov;17(9):2902-13. doi: 10.1007/s10461-013-0539-4.</citation>
    <PMID>23835735</PMID>
  </reference>
  <reference>
    <citation>Avants SK, Margolin A, Usubiaga MH, Doebrick C. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004 Mar;26(2):67-78. doi: 10.1016/S0740-5472(03)00159-4.</citation>
    <PMID>15050083</PMID>
  </reference>
  <reference>
    <citation>Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS Behav. 2018 Apr;22(4):1228-1238. doi: 10.1007/s10461-017-1851-1.</citation>
    <PMID>28695388</PMID>
  </reference>
  <reference>
    <citation>Shrestha R, Karki P, Huedo-Medina TB, Copenhaver M. Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis. J Assoc Nurses AIDS Care. 2017 Jul-Aug;28(4):612-621. doi: 10.1016/j.jana.2017.04.005. Epub 2017 Apr 19.</citation>
    <PMID>28478870</PMID>
  </reference>
  <reference>
    <citation>Shrestha R, Altice FL, Huedo-Medina TB, Karki P, Copenhaver M. Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. AIDS Behav. 2017 May;21(5):1299-1308. doi: 10.1007/s10461-016-1650-0.</citation>
    <PMID>27990587</PMID>
  </reference>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>May 26, 2023</last_update_submitted>
  <last_update_submitted_qc>May 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Michael Copenhaver</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Substance Abuse</keyword>
  <keyword>Pre-Exposure Prophylaxis</keyword>
  <keyword>HIV Risk Behavior</keyword>
  <keyword>Methadone Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03282890
org study id: H17-200
secondary id: R01DA044867
nct id: NCT03282890
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This study will evaluate the efficacy and cost-effectiveness of CHRP-BB - an integrated
      bio-behavioral approach that incorporates the use of PrEP - with an evidence-based behavioral
      approach aimed at enhancing PrEP adherence and HIV risk reduction among high risk PWUD.
PWUD remain a priority population as they represent a critical conduit for new HIV
      infections, which are transmitted through preventable drug- and sex-related HIV risk
      behaviors. Pre-Exposure Prophylaxis (PrEP) - the daily self-administration of antiretroviral
      medication - has enormous potential to bolster primary HIV prevention outcomes among PWUD.
      PrEP is a FDA-approved biomedical HIV prevention strategy recommended by the CDC and WHO for
      key populations, including PWUD. Despite unequivocal evidence supporting PrEP, its scale-up
      has been nearly absent among high risk PWUD. Moreover, adherence to PrEP is crucial if it is
      to be effective with high risk individuals. Recent research, however, indicates that optimal
      PrEP adherence may be compromised by neurocognitive impairment (NCI), particularly among
      PWUD. Due to chronic drug use, related lifestyle experiences, and other health challenges,
      many PWUD experience NCI to the extent that it impedes medication adherence, HIV risk
      reduction, and treatment retention. In a recent HIV prevention trial, over a third of high
      risk PWUD on opioid replacement therapy (ORT) had moderate to high levels of NCI and,
      moreover, were less likely to reduce their HIV transmission risk vs. those without NCI. The
      potentially disruptive impact of NCI must therefore be addressed when designing contemporary
      intervention strategies targeting PWUD. Contemporary approaches must also be cost-effective
      and usable in real-world treatment settings, such as methadone maintenance programs (MMPs)
      where high risk PWUD are concentrated and can be readily reached with primary prevention. To
      date, however, primary prevention efforts have largely relied on singular strategies (e.g.,
      methadone or PrEP alone) with modest HIV risk reduction outcomes for PWUD. Instead, advancing
      combination approaches capable of harnessing the synergy and efficiency possible via multiple
      evidence-based strategies is most effective. This combination strategy is especially
      important when intervening with high risk PWUD with NCI due to the potential decreased
      effectiveness of PrEP when adherence is suboptimal, thereby necessitating behavioral
      interventions that focus on reducing HIV risk and increasing PrEP adherence. Building on
      promising preliminary work, the proposed trial will fill a critical void by testing an
      integrated bio-behavioral approach that incorporates the use of PrEP with an evidence-based
      behavioral approach and, using innovative strategies, enhances PrEP adherence and HIV risk
      behavior in a manner that accommodates NCI among PWUD.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: None (Open Label)
measure: PrEP adherence
time frame: Over a 9-month period
description: PrEP Adherence will be assessed with Dried Blood Spots (DBS) and by self-report using the visual analogue scale (VAS) and pharmacy refill data.
measure: HIV risk reduction behaviors
time frame: Over a 9-month period
description: A self-reported assessment will measure several aspects of HIV risk-taking behaviors, including a measurement of any high risk behavior (sexual or injection-related) as well as measurements of event-level (i.e., partner-by-partner) behaviors. "Any" risk behavior will be dichotomously parsed as those who have engaged in HIV transmission risk behaviors with those of unknown or HIV negative status. Urine toxicology tests will also be used to collect substance use data.
measure: IMB measures related to PrEP adherence and HIV risk reduction
time frame: Over a 9-month period
description: Data collected at all assessment points will include our measure of IMB model constructs, including (a) Information - HIV risk- and PrEP-related knowledge; (b) Motivation - readiness to change and intentions to change PrEP adherence and change HIV risk behavior; (c) Behavioral Skills - PrEP adherence skills and HIV risk reduction skills; and (d) Behavioral Outcomes - HIV risk and HIV risk reduction behaviors and PrEP adherence.
arm group label: CHRP-BB
arm group type: Experimental
description: Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
arm group label: Control Condition
arm group type: No Intervention
description: The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
intervention type: Other
intervention name: CHRP-BB
description: The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
arm group label: CHRP-BB
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Michael Copenhaver, PhD
role: Principal Investigator
affiliation: University of Connecticut
last name: Brian Sibilio, BS
phone: (203) 781-4690
email: brian.sibilio@uconn.edu
last name: Roman Shrestha, PhD
phone: (203) 781-4690
email: roman.shrestha@uconn.edu
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
country: United States
url: http://chip.uconn.edu/
description: University of Connecticut Institute for Collaboration on Health, Intervention, and Policy (InCHIP)
citation: Shrestha R, Altice F, Karki P, Copenhaver M. Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Front Immunol. 2017 May 11;8:561. doi: 10.3389/fimmu.2017.00561. eCollection 2017.
PMID: 28553295
citation: Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L, Copenhaver M. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017 Apr 1;173:107-116. doi: 10.1016/j.drugalcdep.2016.12.023. Epub 2017 Feb 2.
PMID: 28214391
citation: Huedo-Medina TB, Shrestha R, Copenhaver M. Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment. AIDS Behav. 2016 Aug;20(8):1646-57. doi: 10.1007/s10461-016-1394-x.
PMID: 27052845
citation: Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psychol Bull. 1992 May;111(3):455-74. doi: 10.1037/0033-2909.111.3.455.
PMID: 1594721
citation: Shrestha R, Huedo-Medina TB, Altice FL, Krishnan A, Copenhaver M. Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. AIDS Behav. 2017 Nov;21(11):3100-3110. doi: 10.1007/s10461-016-1637-x.
PMID: 28025735
citation: Copenhaver MM, Lee IC, Margolin A. Successfully integrating an HIV risk reduction intervention into a community-based substance abuse treatment program. Am J Drug Alcohol Abuse. 2007;33(1):109-20. doi: 10.1080/00952990601087463.
PMID: 17366251
citation: Copenhaver MM, Lee IC, Baldwin P. A randomized controlled trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment. AIDS Behav. 2013 Nov;17(9):2902-13. doi: 10.1007/s10461-013-0539-4.
PMID: 23835735
citation: Avants SK, Margolin A, Usubiaga MH, Doebrick C. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004 Mar;26(2):67-78. doi: 10.1016/S0740-5472(03)00159-4.
PMID: 15050083
citation: Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS Behav. 2018 Apr;22(4):1228-1238. doi: 10.1007/s10461-017-1851-1.
PMID: 28695388
citation: Shrestha R, Karki P, Huedo-Medina TB, Copenhaver M. Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis. J Assoc Nurses AIDS Care. 2017 Jul-Aug;28(4):612-621. doi: 10.1016/j.jana.2017.04.005. Epub 2017 Apr 19.
PMID: 28478870
citation: Shrestha R, Altice FL, Huedo-Medina TB, Karki P, Copenhaver M. Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. AIDS Behav. 2017 May;21(5):1299-1308. doi: 10.1007/s10461-016-1650-0.
PMID: 27990587
responsible party type: Principal Investigator
investigator affiliation: University of Connecticut
investigator full name: Michael Copenhaver
investigator title: Professor
mesh term: Substance-Related Disorders
sharing ipd: No